RATIONALE AND OBJECTIVES: At present, there is no animal model of breast cancer that forms reproducible microcalcification. The aim of this study was to develop a straightforward, reproducible model system that could be used to develop multimodality contrast agents for the identification of breast cancer microcalcification. METHODS: The R3230 mammary adenocarcinoma cell line was implanted in the mammary fat pad of female Fischer 344 rats (two rats with two implanted tumors and two rats with a single implanted tumor). After growth to 1-2 cm in diameter, tumors were implanted with 100 microm hydroxyapatite crystals (positive control) or calcium oxalate crystals (negative control). Twenty-four hours after crystal implantation, rats were injected intravenously with a previously described near-infrared fluorescent bisphosphonate derivative known as Pam78, and the tumors were imaged using a reflectance optical imaging system. RESULTS: Tumors implanted with hydroxyapatite displayed bright, focal, near-infrared fluorescence in the area of crystal implantation. Control tumors, grown in the same animal and implanted with calcium oxalate, did not display any near-infrared fluorescence, even along the needle track used for crystal implantation. CONCLUSIONS: A simple and rapid animal model of focal calcification in breast cancer tumors has been developed and validated. The model used Pam78, a near-infrared fluorescent contrast agent specific for hydroxyapatite. The potential usefulness of the model for developing similar contrast agents for magnetic resonance and other imaging modalities is discussed.
RATIONALE AND OBJECTIVES: At present, there is no animal model of breast cancer that forms reproducible microcalcification. The aim of this study was to develop a straightforward, reproducible model system that could be used to develop multimodality contrast agents for the identification of breast cancer microcalcification. METHODS: The R3230 mammary adenocarcinoma cell line was implanted in the mammary fat pad of female Fischer 344 rats (two rats with two implanted tumors and two rats with a single implanted tumor). After growth to 1-2 cm in diameter, tumors were implanted with 100 microm hydroxyapatite crystals (positive control) or calcium oxalate crystals (negative control). Twenty-four hours after crystal implantation, rats were injected intravenously with a previously described near-infrared fluorescent bisphosphonate derivative known as Pam78, and the tumors were imaged using a reflectance optical imaging system. RESULTS:Tumors implanted with hydroxyapatite displayed bright, focal, near-infrared fluorescence in the area of crystal implantation. Control tumors, grown in the same animal and implanted with calcium oxalate, did not display any near-infrared fluorescence, even along the needle track used for crystal implantation. CONCLUSIONS: A simple and rapid animal model of focal calcification in breast cancer tumors has been developed and validated. The model used Pam78, a near-infrared fluorescent contrast agent specific for hydroxyapatite. The potential usefulness of the model for developing similar contrast agents for magnetic resonance and other imaging modalities is discussed.
Authors: Ben Brooksby; Brian W Pogue; Shudong Jiang; Hamid Dehghani; Subhadra Srinivasan; Christine Kogel; Tor D Tosteson; John Weaver; Steven P Poplack; Keith D Paulsen Journal: Proc Natl Acad Sci U S A Date: 2006-05-26 Impact factor: 11.205
Authors: Yang Liu; Adam Q Bauer; Walter J Akers; Gail Sudlow; Kexian Liang; Duanwen Shen; Mikhail Y Berezin; Joseph P Culver; Samuel Achilefu Journal: Surgery Date: 2011-05 Impact factor: 3.982
Authors: Sylvain Gioux; Vida Kianzad; Razvan Ciocan; Hak Soo Choi; Chad Nelson; Jeffrey Thumm; Robert J Filkins; Stephen J Lomnes; John V Frangioni Journal: Proc SPIE Int Soc Opt Eng Date: 2008
Authors: Kumar R Bhushan; Preeti Misra; Fangbing Liu; Sanjeev Mathur; Robert E Lenkinski; John V Frangioni Journal: J Am Chem Soc Date: 2008-12-31 Impact factor: 15.419
Authors: Fangbing Liu; Preeti Misra; Elaine P Lunsford; Joanne T Vannah; Yuxia Liu; Robert E Lenkinski; John V Frangioni Journal: Breast Cancer Res Treat Date: 2009-09-17 Impact factor: 4.872